Related Experiment Videos
Antithrombotic therapy in left ventricular thrombosis and systemic embolism
1Department of Medicine, Mt. Sinai School of Medicine, CUNY.
Insights
Left ventricular (LV) thrombi, often linked to myocardial infarction, pose significant health risks. Early detection via echocardiography and anticoagulation are key for prevention, though chronic thrombi treatment remains unclear.
Area of Science:
- Cardiology
- Cardiovascular Imaging
- Thrombosis
Background:
- Left ventricular (LV) thrombi contribute significantly to morbidity and mortality.
- They are frequently associated with acute and chronic myocardial infarction (MI), accounting for 25% of cardiogenic emboli.
- Two-dimensional echocardiography is the preferred noninvasive imaging technique for LV thrombi detection.
Purpose of the Study:
- To review the incidence, timing, and risk factors of LV thrombus formation after myocardial infarction.
- To discuss the implications of LV thrombi for systemic embolization.
- To outline current recommendations for the prevention and treatment of LV thrombi.
Main Methods:
- Literature review of studies on LV thrombi.
- Analysis of data regarding LV thrombus formation in different types of myocardial infarction.
- Evaluation of imaging techniques, particularly echocardiography.
- Review of treatment strategies including anticoagulation and thrombolysis.
Main Results:
- LV mural thrombi are found in one-third of Q-wave anterior MIs, but less than 5% of non-Q wave or inferior MIs.
- Over half of LV thrombi form within 48 hours of acute MI, with nearly all forming within a week.
- LV thrombus development carries a risk of systemic embolization.
Conclusions:
- Anticoagulation with heparin and warfarin for at least 3 months is recommended for patients with large anterior MIs and heart failure to prevent LV thrombosis and embolism.
- Thrombolytic therapy does not decrease LV thrombus formation risk.
- Optimal treatment for chronic LV thrombi is not yet established.
Abstract:
Left ventricular (LV) thrombi are responsible for significant morbidity and mortality in our society. Twenty-five percent of cardiogenic emboli are associated with acute and chronic myocardial infarction. With the development of noninvasive imaging techniques LV thrombi have been increasingly recognized as an important clinical entity; the imaging method of choice is two-dimensional echocardiography. LV mural thrombi occur in one third of Q wave anterior myocardial infarctions; their occurrence in patients with non-Q wave infarction and inferior Q wave myocardial infarction is less than 5%. More than half of all LV thrombi are formed within 48 hours of acute myocardial infarction, and nearly all thrombi have been formed within a week of infarction. The development of an LV thrombus is associated with some risk of systemic embolization. To prevent LV thrombosis and systemic embolism, full-dose heparin followed by warfarin therapy for at least 3 months is indicated for patients with large anterior infarctions and those with heart failure. The use of thrombolytic therapy does not reduce the risk of LV thrombus formation; few data exist on whether early coronary angioplasty reduces the risk of LV thrombus formation and the risk of embolization. The proper treatment for patients with chronic LV thrombi remains unknown.